{'fraction_non_alphanumeric': 0.025100401606425703, 'fraction_numerical': 0.013052208835341365, 'mean_word_length': 5.350318471337579, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A revised role for cyclic AMP in prostaglandin-induced bone resorption.

The effect of cyclic AMP on bone resorption produced by prostaglandin E1 (PGE1) and E2 (PGE2) was studied using 6--7 day-old murine calvarial bones cultured in a chemically defined medium for 48 h. Dibutyryl cyclic AMP inhibited in a dose-related way the prostaglandin-induced mobilization of 45Ca from prelabelled bones. The phosphodiesterase inhibitors, theophylline and 3-isobutyl-methylxanthine, also reduced the release of 45Ca induced by the prostaglandins. It was also found that the doses of the later phosphodiesterase inhibitor needed to inhibit prostaglandin-stimulated mineral mobilization were lower than those needed to reduce unstimulated resorption. The mechanism behind the inhibitory effect of cAMP on prostaglandin-induced bone resorption is unknown, but might be related to the capacity of cAMP to inhibit prostaglandin-stimulated release of lysosomal enzymes, which was also demonstrated in this study.